About Sylvain Thierry

Head of Translational Research, I am a PhD in immuno-virology, with a degree in Immunotherapies and the agreements “FELASA-C/Surgery” for directing animal experimentations. I am a Senior Scientist (21 publications, 2 patents), with 18 years of experience in applied research and 10 years in the development of innovative therapies based on inflammation, DAMPs/PAMPs, oligonucleotides and DNA repair, in the field of infectious diseases (HIV and malaria) and cancers (HCC, HNSCC, NMIBC and hematologic malignancies). An experienced small team leader, autonomous and interactive, I am used to monitoring projects from design to valorization. Driven by my mentors, I am used to working in close cooperation with academics, clinicians and pharmaceutical industries.

#I achieved my thesis in 2006 on DAMPs, inflammation and reactivation of latent human immunodeficiency virus, at the “Cordelliers Research Center” (Pr Vincent Maréchal). I was one of the international precursors to study the “alarmin” properties of the HMGB1 protein.
#I was then recruited for two years as a temporary associate professor at the Paris-6 University. In addition to my teaching, my research focused on the mechanisms of action of cerebral malaria induced by the pfHMGB1 protein, in the team of Pr Dominique Mazié.
#Eager to continue research into medical applications, I joined the Applied-Pharmacology-Laboratory of the Pr Jean-François Mouscadet within the prestigious “ENS Paris-Saclay” as Principal Investigator (obtaining grants from ANRS and Sidaction). During these 5 years, my research focused on the development and characterization of HIV and Cancer treatments (epigenetic remodelers, peptides derived from HMGB1 and integrase inhibitors – WO2013186718).
#I then expanded my expertise on the development of innovative therapies based on oligonucleotides luring the DNA repair machinery (D-baits – AsiDNA). I joined the Curie Institute in the team of Marie Dutreix for 4 years as Coordinator of an INCa-TRANSLA project. I was in charge of directing preclinical studies on head and neck cancers using AsiDNA in combination with radio(arc)therapy and/or anti-PD1/PDL1 ICI. This work led to a successful Phase-I clinical-trial on the systemic administration of AsiDNA in solid cancers (DRIIV-1).
#I recently joined the Tollys company where I contributed to the creation and characterization of a new family of dsRNAs oligonucleotides, as innovative therapy in solid cancers (WO2019211492). I then developed translational research using these drug candidates in different cancer models to reach a clinical-trial.